(Sorry, my teacher mind kicked in here to help us condense the hypotheses so far! )
Therefore, if we interpolate the information from the announcement that we were not stopped for futility, we can reasonably assume, using @kervio and @omnisearch 's models, that...
1) On @omnisearch's models, given a 30% treated mortality, we can safely estimate a range of 83-88 people who have demonstrated an improvement of statistical significance.
2) On @kervio's models, given a 30% treated mortality, I agree with @IronMike94 that its more reasonable to believe that the 'uninformed' prior was used. My reasoning is that these results were going off a lot of the prior information known about C-19 ARDS' inflammatory mechanism of action (M1 macrophage activation, elevated interleukin markers) is very very similar to the MOA in GVHD which provided the 'compelling' evidence for using Rem-L to treat this indication as the results are very clear in how it addresses the inflammation pathways.
Hence, it would not be a 'skeptical' prior, but an 'uninformed' one.
Using the data from the Mt Sinai trial (and the info from the announcement dated 23/04/20), the key results were:
1) 83% (10 out of 12) in ventilator-dependant C-19 patients who were classified as moderate/severe2) 75% (9 out of 12) have come off ventilator support within a median time of 10 days
Conservatively, we can then reasonably assume that the estimated survival rate is at least 70% if the patients in the cohort were moderate/severe in terms of rating on the Berlin Criteria.
Therefore, if we are looking at a survival rate of close to 70%, I can see why we were not halted at 30% for futility, and to add, I believe that there is a very high probability of the trial being stopped due to 'overwhelming efficacy' at the 45% mark, should the survival rate hold true.
O/T: I've absolutely loved the 'productive struggle' (hehe @Wilba32 were you a teacher in a previous life? ) in looking at both models and making some sense of it.
Would love to hear all your thoughts?
- Forums
- ASX - By Stock
- Overwhelming efficacy - the stats required
(Sorry, my teacher mind kicked in here to help us condense the...
-
-
- There are more pages in this discussion • 165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
92.0¢ |
Change
-0.005(0.54%) |
Mkt cap ! $1.056B |
Open | High | Low | Value | Volume |
92.0¢ | 92.5¢ | 91.5¢ | $363.4K | 395.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
26 | 184696 | 91.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.0¢ | 4453 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
29 | 191992 | 0.915 |
19 | 193852 | 0.910 |
9 | 70226 | 0.905 |
41 | 267138 | 0.900 |
7 | 181883 | 0.895 |
Price($) | Vol. | No. |
---|---|---|
0.925 | 43536 | 16 |
0.930 | 97628 | 14 |
0.935 | 72654 | 8 |
0.940 | 16560 | 4 |
0.945 | 126472 | 4 |
Last trade - 10.43am 18/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |